echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Study of Nervous System > Nature Biomedical Engineering: Targeting mitophagy to clear brain "garbage" to treat Alzheimer's disease

    Nature Biomedical Engineering: Targeting mitophagy to clear brain "garbage" to treat Alzheimer's disease

    • Last Update: 2022-01-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    As the world ages, the economic burden of Alzheimer's disease continues to increase, reaching $305 billion in 2020
    .
    At present, about 11% of people over the age of 65 have Alzheimer's disease, and the proportion of people over the age of 85 is as high as 42%


    .


    On January 6, 2022, the research group of Evandro Fei Fang from the University of Oslo in Norway and the research group of Jiahong Lu from the University of Macau published a paper entitled: Amelioration of Alzheimer's disease pathology by mitophagy inducers identified in Nature Biomedical Engineering.
    Research paper on via machine learning and a cross-species workflow
    .

    This study screened a large number of small molecules based on machine learning and found two lead compounds with the potential to treat Alzheimer's disease
    .

    2 lead small molecule compounds have potential to treat Alzheimer's disease

    Xie Chenglong of the First Affiliated Hospital of Wenzhou Medical University, Zhuang Xuxu of the University of Macau, Deruizhi Yao Niu Zhangming, and Ai Ruixue of the University of Oslo, Norway are the co-first authors of this article, and Fang Fei of the University of Oslo, Norway and Lu Jiahong of the University of Macau are the co-corresponding authors
    .

    Fang Fei's group published a paper in Nature Neuroscience in 2019 demonstrating that impaired mitochondrial clearance mechanisms play a key role in the pathogenesis of Alzheimer's disease
    .
    Mitophagy is a mechanism that selectively removes damaged mitochondria through autophagy during cell evolution.


    Timely removal of damaged mitochondria plays an important role in maintaining normal cellular functions


    Modern drug development is expensive, including the screening of compounds for biological activity
    .
    After discovering lead compounds, scientists conduct drug design and compound synthesis based on experience, molecular biologists test compound activity, repeatedly optimize and screen, and finally discover clinical candidate compounds.


    This process often takes 10-20 years


    Fang Fei's team and its collaborators are committed to applying AI for high-efficiency and low-cost screening in the early stage, and performing traditional wet laboratory validation (cells, nematodes, and mice) in the later stage to improve the accuracy of screening drugs.
    The combination of the two parts can accelerate the development of drugs.
    The design ideas can be applied not only in Alzheimer's disease, but also in various medical fields, providing more inspiration for other research groups
    .

    In this study, a new AI technique was established and applied to drug screening : representation learning based on machine learning of 1D, 2D and 3D information for each molecule
    .
    The pre-trained data comes from a total of 19 million small molecule data from ChEMBL and ZINC


    .


    A new AI technology builds and applies drug screening

    The research team clustered and filtered a total of 3724 natural small molecules in the natural small molecule database of the University of Macau
    .
    A total of 18 natural small molecules entered the wet laboratory validation stage


    .


    The study received positive reviews from international peers
    .
    Li-Huei Tsai (MIT, MIT), an international authority on Alzheimer's disease research and a professor in the Department of Brain and Cognitive Sciences at the Massachusetts Institute of Technology, pointed out: "This study used cutting-edge machine learning algorithms to successfully discover new neurons that induce mitochondrial autophagy.


    The candidate drugs were screened by computer, and then validated in multiple systems using cells, Caenorhabditis elegans, and mouse models expressing human P301L Tau protein, and finally two small-molecule compounds, kaempferol and emodin, were found


    Professor Menno Witter, an international authority on brain science research at the Norwegian University of Science and Technology (NTNU), said, "This is an impressive multidisciplinary paper, and Fang Fei's team has very convincingly demonstrated a new method for screening drugs for neurodegenerative diseases.



    In conclusion, this study established a virtual screening algorithm based on AI fusion of multi-dimensional molecular information, and successfully screened out multiple autophagy inducers combined with biological experimental verification to improve the accuracy of AI screening for Alzheimer's disease


    .


    Original source:

    Original source:

    Xie, C.
    , Zhuang, XX.
    , Niu, Z.
    et al.
    Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow .
    Nat Biomed Eng (2022).
    https://doi.
    org /10.
    1038/s41551-021-00819-5.

    Amelioration of Alzheimer's disease pathology by mitophagy inducers identified via machine learning and a cross-species workflowLeave a comment here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.